- Saturday, May 18, 2024
By: PTI
The Drugs Controller General of India (DCGI) on Tuesday (6) approved Bharat Biotech’s intranasal Covid-19 vaccine for restricted emergency use in those aged above 18 years.
“Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Indian health minister Mansukh Mandaviya tweeted.
Big Boost to India's Fight Against COVID-19!
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
He said this step will further strengthen “our collective fight” against the pandemic.
This step will further strengthen our collective fight against the pandemic.
India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership.
With the science-driven approach & Sabka Prayas, we will defeat COVID-19.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
India has harnessed its science, research and development (R&D), and human resources in the fight against Covid-19 under prime minister Narendra Modi’s leadership, he said.
“With the science-driven approach & Sabka Prayas, we will defeat Covid-19,” Mandaviya added.
The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far, company sources had said.
